Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks

Riferimento: 
Leuk Res. 2012 Jul;36(7):841-5.
Autori: 
Huang H, Qin Y, Xu R, You X, Teng R, Yang L, Xu M, Liu H.
Fonte: 
Leuk Res. 2012 Jul;36(7):841-5.
Anno: 
2012
Azione: 
I pazienti con leucemia promielocitica acuta (APL) trovano beneficio dalla combinazione di acido all-trans retinoico (ATRA), triossido di arsenico (ATO), chemioterapia con daunorubicina, questo regime è particolarmente utile per i pazienti con fattori prognostici ad alto rischio.
Target: 
ATRA-ATO-Daunorubicina/leucemia promielocitica acuta.

ABSTRACT
To improve the recovery rate of high-risk patients with acute promyelocytic leukemia (APL), we used all-trans retinoic acid (ATRA)/arsenic trioxide (ATO)/daunorubicin combination in remission induction, daunorubicin and cytarabine in consolidation, and ATRA/ATO/methotrexate ± 6-mercaptopurine in maintenance treatment of APL patients with various risks for relapse. Our results showed a high complete remission rate of 95.3%. Excluding the cases of early-death, no significant differences in event-free survival were observed between the intermediate-risk and high-risk group (p = 0.393) and the low-risk and high-risk group (p = 0.162). In addition, there were no significant differences between the groups in cumulative incidence of central nervous system relapse. In conclusion, our results suggest that APL patients benefit from combination ATO/ATRA/chemotherapy, and that this regimen is especially beneficial for patients with high-risk prognostic factors.

Sostanze: